Study to Evaluate the Safety and Dose-Range of SCH 527123 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Study P04592AM4)(COMPLETED)
This is a two-part study conducted at multiple centers, in subjects with moderate to severe COPD. Part 1 of the study is a double-blind, placebo-controlled, randomized, rising-dose study consisting of four treatment groups enrolled in three cohorts. The duration of treatment, for each cohort, will be a 2-week run-in period, followed by a 12-week double-blind treatment period. Part 2 of the study will be a double-blind, placebo-controlled, randomized, parallel group study consisting of four treatment groups enrolled as one cohort. The duration of treatment will consist of a 2-week run-in period, followed by a 12-week double-blind treatment period.
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Chronic Obstructive Pulmonary Disease
Drug 1: SCH 527123, Drug 2: Placebo to match SCH 527123, Drug 3: SCH 527123, Drug 4: Placebo to match SCH 527123, Drug 5: SCH 527123, Drug 6: Placebo to match SCH 527123, Drug 7: SCH 527123, Drug 8: SCH 527123, Drug 9: SCH 527123, Drug 10: Placebo to matc
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT00441701
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
United States Office Of National Drug Control Policy
A component of the Executive Office of the President established by the Anti-Drug Abuse Act of 1988. The Office establishes policies, priorities, and objectives for national DRUG AND NARCOTIC CONTROL. The goals of the program are to reduce illicit drug use, manufacturing, and trafficking, drug-related crime and violence, and drug-related health consequences.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Neutrophils are thought to play an important role in the pathophysiology of COPD. It is theorized that reducing neutrophil migration to the diseased lung will improve a subject's symptoms...
Given the strong inhibition of SCH 527123 on neutrophil migration to sites of inflammation, there is a theoretical reason for its use in patients with severe asthma where neutrophils are t...
Trial to evaluate the dose response of SCH 527123 in reducing inflammation from an ozone-induced sputum neutrophilia in both healthy subjects and subjects with COPD.
Evaluation of treatment in subjects with mild asthma.
4-Week Safety Study in Subjects with Neutrophilic Asthma
CXCR1 and CXCR2 are G-protein coupled receptors, that have been shown to play important role in tumor growth and metastasis, and are prime targets for the development of novel therapeutics. Here, we r...
Statistical methodologies for human abuse potential studies are rarely evaluated. Human abuse potential studies assess whether test drugs produce positive and negative subjective responses on abuse-re...
Meta-analyses and re-analyses of trial data have not been able to answer some of the essential questions that would allow prediction of placebo responses in clinical trials. We will confront these que...
The calculation of antidepressant-placebo difference (50% - 30% = 20%) in drug trials is based on the postulate that all placebo responders should be 'automatically' antidepressant responders,...
RATIONALE: In a randomised placebo-controlled clinical trial it is assumed that psychosocial effects of the treatment, regression to the mean and spontaneous remission are identical in the drug and pl...